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In Brief
Miller et al. identify a correlation between antagonist-induced receptor thermal stability and G-protein recruitment inhibition via BRET, and use this strategy to obtain two co-crystal structures of the opioid receptor NOP. Docking studies point to a mechanism for antagonistinduced receptor stabilization.
Accession Numbers 5DHH 5DHG

SUMMARY
Understanding the mechanism by which ligands affect receptor conformational equilibria is key in accelerating membrane protein structural biology. In the case of G protein-coupled receptors (GPCRs), we currently pursue a brute-force approach for identifying ligands that stabilize receptors and facilitate crystallogenesis. The nociceptin/orphanin FQ peptide receptor (NOP) is a member of the opioid receptor subfamily of GPCRs for which many structurally diverse ligands are available for screening. We observed that antagonist potency is correlated with a ligand's ability to induce receptor stability (T m ) and crystallogenesis. Using this screening strategy, we solved two structures of NOP in complex with top candidate ligands SB-612111 and C-35. Docking studies indicate that while potent, stabilizing antagonists strongly favor a single binding orientation, less potent ligands can adopt multiple binding modes, contributing to their low T m values. These results suggest a mechanism for ligand-aided crystallogenesis whereby potent antagonists stabilize a single ligand-receptor conformational pair.
INTRODUCTION
G protein-coupled receptors (GPCRs) are intrinsically dynamic cell-surface receptors that play many key roles in human physiology and pathology, mediating the action of more than 30% of clinically marketed drugs (Rask-Andersen et al., 2014) . Structural studies that inform our understanding of GPCRdrug interactions are currently impeded by our lack of understanding surrounding receptor stabilization and its connection to crystallogenesis.
Virtually all of the 31 unique GPCR structures available include ligands that aid in receptor crystallogenesis, with ligand properties such as affinity (pK i ), molecular weight (MW), and lipophilicity (LogP or LogD) affecting the outcome of crystallization trials (Zhang et al., 2015) . In a recent survey of ligands from GPCR co-crystal structures, 77% of ligands were found to possess affinities in the single-digit nanomolar range, 96% of ligands had octanol-water partition coefficients (LogPs) below 5, and 76% had MWs between 200 and 500 Da (Zhang et al., 2015) . As GPCRs are pervasive drug targets, it is not surprising that many ligands that have been developed to target these receptors fall within the well-known Lipinski ''rule of five'' criteria for drug-like compounds (MW %500 Da, LogP %5) (Lipinski, 2004) .
The ability of a ligand to increase a receptor's stability, or melting temperature (T m ), remains the single most predictive metric for identifying promising candidate ligands for crystallization trials, with 92% of crystallized ligand-receptor pairs possessing a T m above 55 C (Alexandrov et al., 2008; Zhang et al., 2015) . Yet the mechanism by which select ligands stabilize the receptor and facilitate GPCR crystallogenesis is not well understood.
To examine the relationship between ligand-induced GPCR stabilization and crystallogenesis, a receptor with an array of structurally diverse, high-affinity ligands such as the nociceptin/orphanin FQ (N/OFQ) peptide receptor (NOP) is ideal. NOP is a member of the opioid receptor subfamily of GPCRs that has emerged as a key drug target due to its developing role in pain transmission, drug addiction, and anxiety, as well as locomotor and mood disorders (Lambert, 2008) . Small-molecule antagonists targeting NOP are under intense investigation for their use as antidepressants (Gavioli and Calo, 2013) , while NOP agonists have shown promise as powerful analgesics that lack abuse liability (Lin and Ko, 2013) . The crystal structure of human NOP in complex with the potent antagonist Banyu Compound-24 (C-24) was recently solved to a resolution of 3.0 Å , revealing the first atomic details of the receptor as well as specific contacts made by C-24 within the orthosteric binding site .
Correlating T m with a ligand's biochemical and functional properties may help to explain the mechanism behind successful crystallogenesis and expedite selection of the most favorable ligands for structural studies.
RESULTS AND DISCUSSION
Distribution of Ligand Properties
Since its discovery in 1994, drug-discovery efforts targeting NOP have produced a variety of agonists and antagonists in the form of both small molecules and peptides (Mollereau et al., 1994; Mustazza and Bastanzio, 2011) . Fortuitously, many of these structurally diverse ligands have high affinities, with dozens of ligands possessing K i values in the low-to sub-nanomolar range.
Using the established CPM thermal stability assay (Alexandrov et al., 2008) , we measured the melting temperatures of 19 NOPligand pairs and evaluated these results with respect to the ligand's MW, calculated LogD, and pK i . As shown in Figure 1A , we observed no correlation between MW and ligand-induced thermal stability of NOP. Likewise, lipophilicity, given as the pH-and pK a -dependent calculated octanol-water partition coefficient LogD, also did not correlate with receptor stability (Figure 1B) . Finally, although single-digit nanomolar affinities were necessary for high thermal stabilities, high binding affinities alone were not sufficient for inducing receptor stabilization, with some high-affinity ligands such as UFP-101 (pK i > 10) conferring limited receptor stability ( Figure 1C ) (Malfacini et al., 2015; McDonald et al., 2003) . These results suggest that although many NOP ligands were developed with exceptional drug-like characteristics, their use in structural studies may be limited by their poor T m values.
Focusing on the six highest-affinity NOP antagonists, we used bioluminescent resonance energy transfer (BRET) to measure the ability of NOP antagonists to inhibit agonist-induced receptor/G-protein interactions ( Figures 1D and S2 ). Rankings of BRET-derived antagonist potencies agreed with those obtained from different functional assays investigating recombinant human (calcium mobilization studies in cells expressing chimeric G proteins) and native animal (in electrically stimulated mouse vas deferens) NOP receptors Goto et al., 2006; McDonald et al., 2002; Trapella et al., 2006 Trapella et al., , 2009 . Comparing these values with NOP-ligand complex thermal stability results, we observed that antagonist Table S1 and primary BRET data are given in Figure S2 .
potency (pK B ) and receptor thermal stability (T m ) are positively correlated (linear regression r 2 = 0.97, p < 0.001).
NOP in Complex with Antagonists SB-612111 and C-35
Having identified SB-612111 and Compound-35 (C-35) as the two next most promising ligands for crystallogenesis, we used lipidic cubic phase (LCP) crystallization to determine the structure of NOP in complex with these two antagonists, both to a resolution of 3.0 Å (for crystallographic statistics, see Table 1 ). The piperidine-based antagonist SB-612111 is a popular tool compound in in vitro and in vivo studies of NOP due to its high affinity (pK i = 9.18) and selectivity (>1,000-fold) toward NOP over classical opioid receptors . The diverse therapeutic potential of SB-612111 has been demonstrated through multiple animal studies in which it has been shown to act as an antidepressant , reduce morphine tolerance (Zaratin et al., 2004) , promote antiparkinsonian effects (Marti et al., 2013) , and ameliorate colitis in animal models of inflammatory bowel diseases (Alt et al., 2012) . C-35 bridges the chemical space between SB-612111 and the previously co-crystallized antagonist C-24, combining the dichlorophenyl head group of SB-612111 with the N-benzyl D-Pro tail from C-24 (for chemical structures, see Table S2 ). During in vitro assays, C-35 displayed high affinity (pK i = 9.14) and selectivity (>300-fold) toward NOP over classical opioid receptors .
A summary of specific ligand-receptor interactions is presented in Figure 2 . In both the SB-612111-and C-35-bound structures, NOP adopts a very similar conformation as in the previously determined NOP-C24 structure, with overall root-mean-square deviations (RMSDs) of 0.37 Å (NOP-SB/ NOP-C24), and 0.45 Å (NOP-C35/NOP-C24) over receptor Ca atoms (Figure 2A ).
Antagonist SB-612111 ( Figure 2B ) is bound by a salt bridge between the protonated nitrogen of the piperidine and D130 3.32 (superscripts following residues indicate Ballesteros-Weinstein Residues in disallowed regions (%)
Ligand electron densities are shown in detail in Figure S1 . NA, data not available.
a Values in parentheses are for the highest-resolution shell.
b Merging R factor:
where I h is the mean intensity of symmetry-equivalent reflections. c Redundancy-independent merging R factor:
where n h is the redundancy of structure factor h, allowing individual reflections be weighted according to their redundancy (Weiss, 2001) .
j describing the precision of the averaged measurement (Weiss, 2001 ).
where F obs and F calc are the observed and calculated structure factor amplitudes, respectively. f Free R factor value was calculated as the R factor for an unrefined subset of reflection data (5% of reflections). g Ramachandran plot was calculated using MolProbity .
Structure 23, 1-9, December 1, 2015 ª2015 Elsevier Ltd All rights reserved 3 numbering throughout the text; Ballesteros and Weinstein, 1995) in a mode that resembles that of C-24 . The dichlorophenyl head group of SB-612111 is buried deep within the hydrophobic sub-pocket outlined by residues M134 3.36 , F135 3.37 , I219 5.42 , and V283 6.55 , while its relatively short heterocyclic tail lies flat against Q107
2.60 at the base of the pocket but does not make direct polar interactions with the receptor. A region of strong electron density in the pocket within the transmembrane core of NOP-SB-612111 is flanked by residues D97 2.50 , N133 3.35 , S137 3.39 , and N311 7.45 ( Figure S3 ). This density is consistent with that of the sodium ion and water cluster identified in the closely related d-opioid receptor and several other class A GPCRs , although a higher-resolution structure is required to unambiguously resolve sodium coordination in NOP.
The binding pose of C-35 ( Figure 2C ) is similar overall to that of SB-612111, with its piperidine nitrogen forming a salt-bridge interaction with D130
3.32 and a hydrogen bond between its amide nitrogen and Q107 2.60 . The dichlorophenyl head group of C-35 is shifted slightly ($0.8 Å ) from that of SB-612111 within the hydrophobic sub-pocket. All three co-crystallized ligands (SB-612111, C-35, and C-24) contain a piperidine group whose protonated nitrogen participates in a salt-bridge interaction with D130 3.32 . Piperidine is a (Ballesteros and Weinstein, 1995) . See also Figure S3 .
ubiquitous building block in NOP ligand design (Mustazza and Bastanzio, 2011) , and the piperidine-D130 3.32 salt bridge common to these structures offers a direct rationalization for the high affinities of this ligand class.
Although the D130 3.32 residue is conserved in all four opioid receptors, it plays a crucial role in binding of the highly selective endogenous agonist N/OFQ (Mouledous et al., 2000; . Because of this, interactions between D130 3.32 and ligands likely contribute to affinity rather than efficacy or selectivity. Notably, the head group of the antagonists described here (a spiroisobenzofuran in C-24 and a dichlorophenyl in C-35 and SB-612111) lies perpendicular to this piperidine ring in all cases, a structural feature previously suggested to be of importance to NOP ligand affinity and efficacy ).
Docking Studies: Degenerate Ligand-Binding Modes Correlate with Low Receptor Stability
To better understand the nature of stabilizing receptor interactions with antagonists and potential conformational changes in the receptor upon their binding, we performed molecular docking of several additional antagonists. We first validated our docking protocol by cross-docking the co-crystallized antagonists in Figure 2 against all three NOP structures in the context of both rigid and flexible receptor side chains. Cross-docking of antagonists C-35, SB-612111, and C-24 into all crystal structures of NOP resulted in accurately reproduced binding poses with RMSDs ranging from 0.6 to 1.3 Å (Table S3) . Moreover, energy-based refinement of these compounds with extensive flexible sampling of binding pocket side chains resulted in only very minor variations in receptor and ligand conformations.
In contrast, docking of antagonist J-113397 and key derivatives based on the compound's 4-(2-keto-1-benzimidazolinyl)-piperidine scaffold suggests substantial differences in the receptor interactions with compounds of this chemotype (Kawamoto et al., 1999) . Docking of J-113397 into the rigid NOP structure led to an unexpected, flipped orientation (deemed mode II) of the piperidine ring compared with co-crystallized ligands ( Figure 3A , right panel). Analysis of this binding mode suggests that the ethyl moiety on the benzimidazolinyl ring of J-113397 prevents it from binding in the unflipped orientation (mode I) due to a severe steric clash between the ethyl group and the Q280 6.52 side chain. However, allowing conformational sampling of receptor side chains and water during docking allowed J-113397 to bind in an orientation similar to that of the co-crystallized ligands (mode I), with a comparable free energy of binding ( Figure 3A, left panel) .
Similarly to J-113397, a flip between predicted rigid and flexible receptor docking conformations was observed for Trap-101 ( Figure 3B ), an achiral analog of J-113397 with a double bond introduced between C3 and C4 positions of the piperidine ring (Trapella et al., 2006) . Interestingly, the 3-hydroxymethyl moiety of J-113397 and Trap-101 in mode I points deep into the pocket, forming additional hydrogen bonds with both the D130 3.32 side chain and the adjacent water molecule observed in the crystal structure ( Figure S4 ). This tight binding of the 3-hydroxymethyl group is supported by previous structure-activity relationship studies, which show that replacement of the 3-hydroxymethyl with a bulkier COOCH 3 moiety reduces binding of both J-113397 and Trap-101 by about 100-fold (Trapella et al., 2006) . The residual binding of the Trap-101 3-COOCH 3 derivative suggests that this chemotype can still bind in an alternative conformation, likely similar to the flipped, mode II conformation observed in rigid docking, albeit with greatly reduced affinity. Multiple predicted binding modes were also observed for highaffinity antagonist JTC-801, which adopted a distinct binding mode buried in the crevice between helices 4 and 5 ( Figure S4 ).
A Mechanism for Stabilization: Ligand-Receptor Conformational Pairs Analysis of the aforestated docking results (Figure 3 ) in the context of thermostability data for these ligands (Figure 1 ) suggests that the tight and unique binding poses of compounds such as C-24, C-35, and SB-612111 may be one of the prerequisites for complex thermostabilization and conformational stabilization that are critical for successful crystallogenesis. Thus, compounds with at least two predicted alternative binding poses, J-113397, Trap-101, and JTC-801, had reduced T m values and were not amenable for crystallization. Interestingly, the peptide antagonist UFP-101 was not shown to significantly stabilize NOP despite its exceptional sub-nanomolar affinity ( Figure 1D ) (McDonald et al., 2003) . Docking of UFP-101 in our previous study showed that its interactions with NOP were primarily electrostatic in nature, with multiple positively charged residues in the C terminus (residues 5-17) of UFP-101 binding to negatively charged receptor side chains at the entrance of the binding pocket. Such interactions are likely to be non-specific, with the numerous rotatable bonds of UFP-101 allowing alternative salt-bridge pairings of positively and negatively charged side chains, which further corroborates the potential link between the multiplicity of ligandbinding conformations and reduced thermostability.
Future Outlook: Ligand-Receptor Interactions and Crystallization Understanding GPCR signal transduction begins with detailed knowledge of ligand-receptor interactions. Toward this aim, identification of ligands that facilitate crystallogenesis for GPCR structural studies is a major bottleneck, and has been limited by our lack of understanding surrounding receptor stabilization and its connection to crystallogenesis.
High receptor thermal stability (T m ) has become a hallmark of pre-crystallization trials for GPCRs, as ligands that stabilize the receptors are thought to aid in folding and increase the dwell time of the receptor in the desired conformational state. The linear relationship between ligand-induced T m and antagonist potency (pK B ) provides us with another potential avenue by which candidate ligands for crystallization may be identified. Unlike T m measurements, pK B values derived from BRET assays can be measured using crude membrane preparations and, in the case of b-arrestin variations on the assay, whole cells, such that protein purification is no longer required. Due to the ease of sample preparation, the BRET assay is more amenable to adaptation as a high-throughput tool for ligand screening purposes specifically for GPCR structural studies. Table S2 , explicit free energies of binding can be found in Table S3 , and detailed ligand-receptor interactions are shown in Figure S4 .
Intensifying efforts to determine the relationship between conformational heterogeneity and receptor stability have resulted in a wealth of hypotheses surrounding the mechanism of GPCR activation, as well as the influence of ligands on these processes (Bock et al., 2014; Liu et al., 2012; Manglik et al., 2015; Nygaard et al., 2013; Vaidehi et al., 2014) . In the present study, we determined the crystal structures of NOP in complex with antagonists SB-612111 and C-35, extending the findings of the previously reported antagonist-bound structure of NOP bound to C-24. We also demonstrate a strong correlation between antagonist pK B and thermostability, thus highlighting a highthroughput strategy for identifying GPCR ligands for crystallization. The increase in thermostability is consistent with a reduction in receptor flexibility by shifting the conformational equilibrium exclusively to the antagonized state. Docking studies indicate that these potent antagonists, such as SB-612111, have a single permissible binding mode that promotes a uniform local conformation, high receptor stability, and isolation via crystallization ( Figure 4A ). In contrast, ligands that adopt multiple binding poses (such as J-113397, Trap-101, JTC-801, and UFP-101) divide the receptor population by the number of binding orientations ( Figure 4B) ; the resulting conformational heterogeneity decreases receptor stability as well as the probability of isolating one receptor-ligand conformational pair via crystallization.
Because GPCRs maintain a dynamic equilibrium between several conformational states corresponding to various signaling events (Audet and Bouvier, 2012; Liu et al., 2012) , an analogous link between the degeneracy of receptor-ligand conformational pairs and crystallization could potentially be extended to active-state receptors. While the multiplicity of ligand-binding modes stunts crystallization of inactive-state (antagonist-bound) receptors, this degeneracy is further amplified in the presence of agonists by virtue of multiple active-state conformations (Manglik et al., 2015) . Thus, selecting an agonist with a single preferred binding orientation and strong conformational selectivity towards one specific receptor substate over others may boost receptor conformational homogeneity and the likelihood of crystallogenesis.
Together, our results not only suggest a potential mechanism for antagonist-induced receptor stabilization, but also point to new avenues for identifying receptor-ligand pairs that are most amenable to structural studies. Such advances in our understanding of ligand-receptor interactions will aid in the goal of understanding GPCR structural biology.
EXPERIMENTAL PROCEDURES
Chemical Compounds
The N/OFQ peptide was synthesized in-house following the procedures previously described in detail (Guerrini et al., 1997) . The non-peptide molecules C-35, C-24, Trap-101, and J-113397 were synthesized in-house by C.T. SB-612111 was from Tocris Bioscience. All tissue culture media and supplements were from Invitrogen. Reagents used were from Sigma Chemical or Merck, and were of the highest purity available. Native coelenterazine (CLZN, 5 mM, EtOH) was from Synchem UG. N/OFQ was dissolved in ultrapure water (1 mM) while other ligands were dissolved in DMSO (10 mM) and kept at À20 C until use.
Cell and Membrane Preparation for BRET Assay
Human embryonic kidney (HEK293) cells were grown in DMEM supplemented with 10% (v/v) fetal calf serum, 100 units/ml penicillin G, and 100 ng/ml streptomycin sulfate, in a humidified atmosphere of 5% CO 2 at 37 C. Cell lines permanently co-expressing NOP-RLuc and Gb 1 -RGFP were prepared using the pantropic retroviral expression system by Clontech as described previously (Malfacini et al., 2015; Molinari et al., 2008) . NOP/G-protein interaction experiments were performed in enriched plasma membrane aliquots from transfected cells prepared by differential centrifugation. In brief, cells were detached with 1 mM PBS/EDTA solution (pH 7.4 adjusted with NaOH) then, after 5 min of centrifugation at 500 3 g, Dounce-homogenized (30 strokes) in cold homogenization buffer (5 mM Tris, 1 mM EGTA, 1 mM DTT [pH 7.4 adjusted with HCl]) in the presence of 0.32 M sucrose. Three following centrifugations were performed at 1,000 3 g (4 C) and the supernatants kept. Two subsequent centrifugations at 25,000 3 g (4 C) (the second in the absence of sucrose) were performed to separate enriched membranes which, after discarding the supernatant, were kept in ultrapure water at À80 C (Vachon et al., 1987) . The protein concentration in membranes was determined using the QPRO-BCA kit (Cyanagen) and a Beckman DU 520 spectrophotometer.
BRET Assays
Membrane bioluminescence was recorded in 96-well untreated white opaque microplates (PerkinElmer). For the determination of NOP/G-protein interaction, membranes (3 mg of protein) prepared as described above were added to wells in Dulbecco's PBS. NOP/G-protein interactions were measured in the presence of CLZN (5 mM, injected 10 min prior to reading the cell plate) in cell membranes; the contribution of other cellular processes (i.e., arrestin recruitment, internalization) was hence negligible. Increasing concentrations of N/OFQ were added in 20 ml of 0.01% PBS-BSA (BSA; Sigma Chemical) 15 min before reading luminescence. Luminescence signals were measured as counts per second with a Victor X 2030 luminometer (PerkinElmer). Emissions were selected using 460 nm (25 nm bandwidth) and 510 nm (10 nm bandwidth) band-pass filters for Rluc and RGFP, respectively. All BRET experiments were performed at room temperature.
BRET Assay Data Analysis
Concentration-response curves to N/OFQ were carried out in the absence and presence of a fixed concentration of each antagonist. Antagonists were added to membranes 15 min prior the addition of concentration-response curves to N/OFQ. Following agonist injection, re-equilibration was allowed by leaving agonist/antagonist to compete for 15 min before the measurement of BRET ratio. All data were computed as stimulated BRET ratio units, i.e., the ratio between counts per second from RGFP and RLuc in the presence of ligands, followed by baseline subtraction, i.e., the BRET value in the absence of ligand. Maximal agonist effects (E max ) were expressed as a fraction of the N/OFQ E max , which was determined in every assay plate and reported as E/E max , in the graphs in Figure S2 . Concentration-response curves to agonists and inhibition response curves to antagonists were analyzed with a four-parameter logistic non-linear regression model. Agonist data are expressed as mean ± SEM of n experiments.
Antagonist potencies were derived with the equation pK B = ðlogðCR À 1ÞÞ À log½½B, where CR is the ratio between agonist potency (expressed as EC 50 ) in the presence and absence of antagonist, and [B] is the molar concentration of antagonist. Antagonist pK B values were derived from at least four experiments performed in duplicate and are reported as mean ± CL 95% . The value pK B is the negative logarithm of the equilibrium dissociation constant of an antagonist-receptor complex as determined through a functional assay in which a physiological response is antagonized. In other words, K B is the concentration of antagonist that occupies half of the receptor population at equilibrium, expressed in units M. Curve fitting was performed using PRISM 5.0 (GraphPad Software).
Protein Expression and Purification for Crystallogenesis
The human NOP receptor structures presented here use a previously described fusion-partner construct and expression scheme . Details of receptor expression and purification are available in the Supplemental Experimental Procedures. Receptor purity and monodispersity were monitored via SDS-PAGE and analytic size-exclusion chromatography throughout purification. Typically, protein from 5 l of Spodoptera frugiperda (Sf9) insect cell biomass was concentrated to 20 ml to yield a concentrated solution of 40 mg/ml appropriate for one round of crystallization.
Lipidic Cubic Phase Crystallization
Concentrated protein samples were reconstituted into the LCP by mixing with molten lipid using a mechanical syringe mixer at room temperature ($20 C-22 C) (Caffrey and Cherezov, 2009 ). The LCP mixture contained 40% (w/w) concentrated protein, 54% (w/w) monoolein (Sigma), and 6% (w/w) cholesterol (Avanti Polar Lipids). Crystallization trials were performed in 96-well glass sandwich plates (Marienfeld) (Cherezov et al., 2004) onto which 40 nl of protein-containing LCP drops and 0.8 ml of precipitant solution were deposited by the NT8-LCP (Formulatrix) or mosquito LCP (TTP Labtech) crystallization robots. The crystallization plates were then sealed with a glass coverslip and stored at 20 C in an incubator/imager (RockImager 1000, Formulatrix). Diffraction quality crystals were grown and harvested after about $20 days in 25%-35% (v/v) polyethylene glycol 400, 130-200 mM potassium sodium tartrate tetrahydrate, and 100 mM Bis-Tris propane (pH 6.4). Crystals were collected directly from LCP using 50 mm MiTeGen micromounts and immediately flashfrozen in liquid nitrogen.
X-Ray Data Collection and Processing
X-Ray data were collected at the 23ID-B/D beamline (GM/CA-CAT) at the Advanced Photon Source, Argonne National Laboratory, using a 10-mm collimated minibeam with X-ray wavelength of 1.0330 Å and a MarMosaic 300 CCD detector. Due to radiation damage, typically 10 -20 wedges of data were collected from each crystal at 100 K using an unattenuated beam, with 1 of oscillation and 1-2 s of exposure, before changing the crystal.
Structure Determination and Refinement
Initial phases were obtained by molecular replacement with Phaser-MR (McCoy, 2007) maximum-likelihood molecular replacement using the original NOP-C24 structure as a search model (PDB: 4EA3, ligands removed, BRIL and transmembrane domains searched for separately). Each asymmetric unit contains two antiparallel receptors and one BRIL fusion partner. The second BRIL fusion was not observed in any of the reported NOP structures, likely due to disorder. Model building was performed with Coot (Emsley et al., 2010) , while structural refinement was carried out with PHENIX (Adams et al., 2010) .
Crystallographic R work , as well as R free for 5% of the reflections excluded from the refinement, were calculated to monitor the structural refinement procedures. The results of the structural analysis are summarized in Table 1 . Structural validation was performed using MolProbity . All molecular graphics were produced with PyMOL molecular graphics system v.1.4.1 (Schroedinger).
Docking Assessment of Crystal Structures
Both rigid and flexible docking of small-molecule ligands into the available crystal structures of NOP were performed using Internal Coordinate Mechanics (ICM) molecular modeling suite (Tables S2 and S3 ; Figure S4 ) (Abagyan et al., 1994 (Abagyan et al., , 2009 . For the rigid receptor docking, receptor models were prepared from crystal structures by assigning and optimizing conformations of hydrogen atoms and generating the set of grid potential maps of the receptor in a 30 3 30 3 30-Å box covering the extracellular half of the receptor. Ligand docking is based on biased probability Monte Carlo optimization of the ligand internal coordinates (Totrov and Abagyan, 1997) . Compounds in 2D representation were converted to 3D and energy optimized using the MMFF-94 force field (Halgren, 1995) ; at least ten random orientations of the ligand were used as starting conformations.
Monte Carlo sampling and optimization were performed at high thoroughness = 30. The objective energy function included the ligand internal strain and a weighted sum of the grid map values in ligand atom centers. For the flexible receptor docking, we used an explicit all-atom representation of the receptor, where side chains within 6 Å of the ligand were considered flexible. Extensive sampling of the ligand and side-chain conformations in the binding pocket was performed using ICM global energy optimization (Totrov and Abagyan, 1997) .
To ensure convergence of the Monte Carlo optimization, five independent runs of the docking procedure were performed, and the resulting poses compared. The docking results of individual docking runs for each compound were considered consistent if at least three of the docking runs produced similar ligand conformations with RMSD < 2.0 Å and binding score < À14.0 kJ/mol. The ICM ligand-binding score (Bursulaya et al., 2003; Schapira et al., 1999) was calculated as:
S bind = E int + TDS Tor + E vw + a 1 3 E el + a 2 3 E hb + a 3 3 E hp + a 4 3 E sf , where E vw , E el , E hb , E hp , and E sf are van der Waals, electrostatic, hydrogen bonding, non-polar, and polar atom solvation energy differences between bound and unbound states, E int is the ligand internal strain, DS Tor is its conformational entropy loss upon binding, T = 300 K, and a i are ligand-and receptorindependent constants. No distance restraints or any other experimentally derived information was used in the ligand docking procedure.
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Supplemental Experimental Procedures Protein Expression and Purification
The human NOP receptor structures presented here use a previously described construct and purification scheme, with modifications as described below . Recombinant baculoviruses were generated using the Bac-to-Bac system (Invitrogen) and were used to infect Spodoptera frugiperda (Sf9) insect cells at a density of 2 × 10 6 cells ml −1
at a multiplicity of infection of 5. Infected cells were grown at 27 °C for 48 h before being collected, and the cell pellets were stored at −80 °C.
Insect cell membranes were disrupted by dounce homogenization of cell pellets in a hypotonic buffer containing 25 mM HEPES, pH 7.5, 10 mM MgCl 2 , 20 mM KCl and protease inhibitor cocktail (Roche).
Extensive washing of the membranes was performed consecutively by repeated dounce homogenization and centrifugation in a high osmotic buffer containing 1.0 M NaCl, 10 mM MgCl 2 , 20 mM KCl and 25 mM HEPES, pH 7.5 (three times). Purified membranes were resuspended in 500 mM NaCl, 20 mM KCl, 50 mM HEPES, pH 7.5, and 35% (v/v) glycerol, flash frozen with liquid nitrogen, and stored at −80 °C until further use.
Purified membranes were thawed on ice and incubated with either 25 μM C-35 (synthesized by C.
Trapella and R. Guerrini as in ) or 50 μM SB-612111 (Tocris), in a solution of 500 mM NaCl, 50 mM HEPES pH 7.5, 20 mM KCl, and 5% glycerol (v/v), at 4 °C for 60 min. Iodoacetamide appropriate for one round of crystallization.
